Hyperfractionation versus Conventional Fractionation of Preoperative Intensity-Modulated Radiotherapy with Oral Capecitabine in Locally Advanced Mid-Low Rectal Cancer: A Propensity Score Matching Study

Abstract

Purpose. In theory, the hyperfractionated radiotherapy can enhance biological effect dose against tumor and alleviate normal tissue toxicity. This study is to assess the efficacy and safety of preoperative hyperfractionated intensity-modulated radiotherapy (IMRT) with oral capecitabine in patients with locally advanced rectal cancer (LARC). Methods. We retrospectively screened patients with LARC from January 2015 to June 2016. Patients that received hyperfractionated IMRT or conventional fractionated IMRT were eligible in the hyperfractionation (HF) group or conventional fractionation (CF) group, respectively. The primary outcome was the complete response rate. Secondary outcomes included toxicity, postoperative complications, anus-reservation operation rate, local recurrence and distant metastases rate, overall survival (OS), cancer-specific survival (CSS), and disease-free survival (DFS). Results. 335 patients were included in the analysis. The complete response rate for the hyperfractionated and conventional fractionated IMRT was 20.41% vs. 23.47% ( $P=0.583$ ). The anus-reservation operation rate was 68.37% vs. 65.31% ( $P=0.649$ ). There were no cases of grade 4 toxicity during radiotherapy; the rate of grade 3 toxicity and postoperative complications was both comparable between groups. However, in the CF group, more patients had a second operation due to complications (0.0% vs. 5.68%, $P=0.011$ ). The cumulative local regional recurrence and distant metastases rates of the HF group and CF group were 5.10% vs. 9.18% ( $P=0.267$ ) and 22.45% vs. 24.49% ( $P=0.736$ ), respectively. The 5-year OS, CSS, and DFS in the HF group and CF group were 86.45% vs. 73.30% ( $P=0.503$ ), 87.34% vs. 75.23% ( $P=0.634$ ), and 70.80% vs. 68.11% ( $P=0.891$ ), respectively. Conclusions. The preoperative hyperfractionated IMRT with oral capecitabine, with an acceptable toxicity and favorable response and survival, could reduce the rate of secondary surgery.